Sign in
Baseline Characteristics of Patients Maintaining q12 and q16 Dosing With Aflibercept 8 mg vs Patients With Shortened Treatment Intervals Phase 3 PULSAR Post Hoc Analysis
David R. Chow, MD, FRCS(C)
Annual Meeting Talks
2023
Episode 158: Journal Club with Dr. Ajay Kuriyan and Dr. Shriji Patel, IVR versus IVA for wet AMD, Protocol T subanalysis, CSR natural history
Jayanth Sridhar, MD
Member Podcasts
2018
Real World Patient and Clinical Characteristics in Treatment Naive Neovascular Age-Related Macular Degeneration
Matthew P. Ohr, MD
On Demand Cases, Courses, and Papers
2019
Category: Neovascular AMD